Exhibit 99.1 LeMaitre Q3 2025 Financial Results BURLINGTON, MA, November 6, 2025 – LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q3 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q3 2025 results include a non-recurring benefit from the Employee Retention Tax Credit. Non-GAAP adjusted figures exclude this benefit. A reconciliation of GAAP to non-GAAP results is included. Q3 2025: Grafts (+23%) and Shunts (+1 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 OR 1585 Broadway 10036 New York, NY (Zip Code) (Address of principal executive offices) 1 (212) 761-4000 (Registrant's telephone number, including area code) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________ FORM 10-Q ________________________ (Mark One) or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number 001-40860 ________________________ Olaplex Holdings, Inc. (Exact name of registrant as specified in its charter) ________________________ Delaware 87-1242679 (State or other juri ...

Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS Organizational restructuring and operating cost reduction initiatives on track SAN DIEGO, Calif., — November 6, 2025 — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2025, together with other business updates. Quarterly Results: • Revenue of $41.6 ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Johanna Schmitt Mark Stoutenberg Media Relations Investor Relations Akamai Technologies Akamai Technologies Revenue: Revenue was $1.055 billion, a 5% increase over third quarter 2024 revenue of $1.005 billion and a 4% increase when adjusted for foreign exchange.* Revenue by solution: Cloud Infrastructure Services** revenue of $81 million, up 39% year-over-year and when adjusted for foreign exchange* GAAP net income per diluted share of $0.97, up 155% year-over-ye ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39606 SoFi Technologies, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39603 REVELATION BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 84-3898466 | | --- | --- | | ( State or other jurisdicti ...

BILL Reports First Quarter Fiscal Year 2026 Financial Results SAN JOSE, Calif.--(BUSINESS WIRE) – November 6, 2025 – BILL (NYSE: BILL), the intelligent finance platform trusted by half a million businesses to manage, move and maximize their money, today announced financial results for the first fiscal quarter ended September 30, 2025. "We started fiscal 2026 with strong momentum, expanding BILL's reach and delivering a significant beat on profitability, all while leading a new era of intelligent financial o ...

Exhibit 99.1 Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights SOUTH SAN FRANCISCO, Calif., – November 6, 2025 – Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2025, and provided business highlights. "Momentum is building across Denali as we prepare for the anticipated launch of tividenofusp alfa with an experienced and focused commercial team in place," said Ryan Watts, Ph.D., Chief Executive Officer ...

Exhibit 10.2 Execution Version AMENDMENT NO. 1 TO CREDIT AGREEMENT This Amendment No. 1 dated as of November 5, 2025 (this "Amendment") by and among GoPro, Inc., a Delaware corporation (the "Borrower"), the Lenders party hereto and Farallon Capital Management, L.L.C. in its capacity as administrative agent for Lenders and as collateral agent for itself and the other Secured Parties (the "Agent"). W I T N E S S E T H: WHEREAS, the Borrower, the Lenders from time to time party thereto and the Agent are partie ...